

Enoxaparin Brand switch

Ashford & St. Peter's Hospitals NHS Foundation Trust (ASPH) are changing the brand of enoxaparin prescribed at the Trust from Clexane® to the biosimilar product Inhixa®. There is no difference in dosing or licensing between Inhixa® and Clexane®.

Biosimilars (e.g. Inhixa®) are considered interchangeable with their reference product (i.e. Clexane®), however, as per [MHRA advice](#), **prescribing should be by brand name** as this supports pharmacovigilance and continuity of supply for the patient.

There are limited indications for which enoxaparin should be prescribed in primary care. [See Surrey Prescribing Advisory Database \(PAD\)](#) for further details. Where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.

Please note:

Clexane® pre-filled syringes are presented with an automatic needle safety guard which is activated when the full dose has been administered.

Inhixa® pre-filled syringes have a needle safety guard that activates when the needle is withdrawn after administration of the full dose and the plunger is pressed in further.

Inhixa® also has different colour coding to the originator Clexane® .



It is therefore important that the patient receives the same brand that they have been initiated and given training on.

Please click on the link for a video demonstrating the administration of Inhixa® : [Patient Video_Techdow Pharma England Ltd \(techdow-pharma.co.uk\)](http://techdow-pharma.co.uk)

Further resources (including patient instruction leaflets) and training to support the use of Inhixa® can be obtained from: Claire Burton - claire.burton@techdow.co.uk